SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:oru-110308"
 

Sökning: id:"swepub:oai:DiVA.org:oru-110308" > Health-Related Qual...

  • Bergthorsdottir, RSahlgrenska University Hospital, Gothenburg, Sweden (författare)

Health-Related Quality of Life In Patients With Adrenal Insufficiency Receiving Plenadren Compared With Immediate-Release Hydrocortisone

  • Artikel/kapitelEngelska2015

Förlag, utgivningsår, omfång ...

  • Elsevier,2015
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-110308
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-110308URI
  • https://doi.org/10.1016/j.jval.2015.09.2145DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-124656URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • BackgroundPrevious studies in patients with primary adrenal insufficiency (PAI) on conventional replacement therapy suggest decreased health-related quality of life (HRQoL), and that patients report more frequently fatigue, increased anxiety and inability to work compared to background population.ObjectivesTo study self-reported health status with EQ-5D in patients with PAI. Patients treated with Plenadren (modified-release hydrocortisone) were compared with patients treated with immediate release hydrocortisone (IRHC) replacement therapy.MethodsThis was a cross-sectional, multi-centre, non-interventional survey of patients with PAI receiving Plenadren or immediate release hydrocortisone (IRHC) replacement.SubjectsOne hundred thirty-four adult patients with PAI of whom 36 (19 females [53%]) were treated with Plenadren and 98 (77 females [79%]) were treated with IRHC, were included.MAIN OUTCOME MEASUREHRQoL described by the EQ-5D, a generic preference-based measure of health.RESULTSPatients on Plenadren and on IRHC had a mean ± SD age of 53.1 ± 12.7 years and 48.0 ± 13.1 years, respectively (P=0.043). The majority of the patients were diagnosed more than 5 years ago (69%). The mean ± SD daily Plenadren and IRHC doses were 27.0 ± 6.8 mg and 26.6 ± 10.9 mg, respectively (P=0.807). 47% of the Plenadren patients had been receiving Plenadren and 82% of the IRHC patients had been receiving IRHC for more than 3 years. Patients receiving Plenadren had better HRQoL measured by the EQ-5D questionnaire compared to patients replaced with IRHC (0.76 ± 0.18 vs 0.68 ± 0.18, respectively [P=0.040]).CONCLUSIONSReplacement therapy with Plenadren in patients with PAI confers measurable benefit on HRQoL relative to IRHC as estimated by the EQ-5D questionnaire, and may therefore be advantageous when compared to IRHC substitution.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Nilsson, A GSahlgrenska University Hospital, Gothenburg, Sweden (författare)
  • Gillberg, PShire, Danderyd, Sweden (författare)
  • Ekman, BertilLinköpings universitet,Östergötlands Läns Landsting,Endokrinmedicinska kliniken,Avdelningen för kardiovaskulär medicin,Medicinska fakulteten(Swepub:liu)berek83 (författare)
  • Wahlberg, Jeanette,1969-Linköpings universitet,Östergötlands Läns Landsting,Endokrinmedicinska kliniken,Avdelningen för kardiovaskulär medicin,Medicinska fakulteten(Swepub:liu)jeawa98 (författare)
  • Sahlgrenska University Hospital, Gothenburg, SwedenShire, Danderyd, Sweden (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Value in Health: Elsevier18:71098-30151524-4733

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy